Mark E. Cooper
0000-0001-7785-2488
Publication & Citation Trends
Publications
706 total
Activator protein-1 (AP-1) inhibition prevents endothelial to mesenchymal transition in diabetes-associated atherosclerosis: a translational study
Cited by 0
Semantic Scholar
Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease
Cited by 0
Semantic Scholar
#468 Regulation of renal fibrosis via the RAGE pathway by miR-214 and host ncRNA in diabetic kidney disease
Cited by 0
Semantic Scholar
Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes OA
Cited by 9
Semantic Scholar
The role of activator protein-1 (AP-1) complex in diabetes associated atherosclerosis: Insights from single cell RNA sequencing. OA
Cited by 11
Semantic Scholar
Elucidating NOX5 as a Potential Therapeutic Target and a Biomarker of Kidney Disease in Diabetes
Cited by 0
Semantic Scholar
Characterising the Pro-Oxidant Enzyme NOX5 as a Potential Therapeutic Target for Diabetic Kidney Disease
Cited by 0
Semantic Scholar
Lipoxins Protect Against Diabetic Kidney Disease by Attenuating the Expression of Inflammatory Genes
Cited by 0
Semantic Scholar
Research Topics
Chronic Kidney Disease and Diabetes
(212)
Advanced Glycation End Products research
(154)
Diabetes Treatment and Management
(145)
Blood Pressure and Hypertension Studies
(105)
Renin-Angiotensin System Studies
(70)
Affiliations
Université Claude Bernard Lyon 1
Rutgers, The State University of New Jersey
AstraZeneca (United Kingdom)
Kurume University
University of Copenhagen